F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 28, 2015, Pages 8632-8637

  Malonia, Sunil K ^a   Dutta, Parul ^b   Santra, Manas Kumar ^b   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

DNA damage; FBXO31; MDM2; P53; Tumor suppressor

Indexed keywords

F BOX PROTEIN; F BOX PROTEIN 031; PROTEIN MDM2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SERINE; UNCLASSIFIED DRUG; ATM PROTEIN; ATM PROTEIN, HUMAN; FBXO31 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; MUTAGENIC AGENT; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME PHOSPHORYLATION; GENOTOXIC STRESS; GROWTH DISORDER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOLID TUMOR; STRESS; CELL DIVISION; CELL LINE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL DIVISION; CELL LINE; DNA DAMAGE; F-BOX PROTEINS; HUMANS; MUTAGENS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84937150672     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510929112     Document Type: Article

References (39)

1. Kumari R, Kohli S, Das S (2014) p53 regulation upon genotoxic stress: Intricacies and complexities. Mol Cell Oncol 1(3):e969653.
2. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629.
3. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307-310.
4. Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13(2):83-96.
5. Itahana K, et al. (2007) Targeted inactivation ofMdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12(4):355-366.
6. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132(3):363-374.
7. Skaar JR, Pagan JK, Pagano M (2013) Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol 14(6):369-381.
8. Ho MS, Tsai PI, Chien CT (2006) F-box proteins: The key to protein degradation. J Biomed Sci 13(2):181-191.
9. Santra MK, Wajapeyee N, Green MR (2009) F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459(7247):722-725.
10. Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1(5):a001883.
11. Liu J, et al. (2014) F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6). J Biol Chem 289(31):21508-21518.
12. Cheng Q, Chen J (2010) Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 9(3):472-478.
13. Wang Z, et al. (2012) DNA damage-induced activation of ATM promotes β-TRCP-mediated Mdm2 ubiquitination and destruction. Oncotarget 3(9):1026-1035.
14. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282(5393):1497-1501.
15. el-Deiry WS, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75(4):817-825.
16. Waldman T, Kinzler KW, Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55(22):5187-5190.
17. Kumar R, et al. (2005) FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res 65(24):11304-11313.
18. Fang L, et al. (1999) p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18(18):2789-2797.
19. Wang Y, Blandino G, Givol D (1999) Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18(16):2643-2649.
20. Khosravi R, et al. (1999) Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 96(26):14973-14977.
21. Maya R, et al. (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev 15(9):1067-1077.
22. Ogawara Y, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277(24):21843-21850.
23. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98(20):11598-11603.
24. Zhang T, Prives C (2001) Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J Biol Chem 276(32):29702-29710.
25. Inuzuka H, et al. (2010) Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 18(2):147-159.
26. Lai KP, et al. (2010) S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 29(17):2994-3006.
27. Hickson I, et al. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64(24):9152-9159.
28. Blasina A, Price BD, Turenne GA, McGowan CH (1999) Caffeine inhibits the checkpoint kinase ATM. Curr Biol 9(19):1135-1138.
29. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241-5248.
30. Bettayeb K, et al. (2008) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27(44):5797-5807.
31. Rena G, Bain J, Elliott M, Cohen P (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 5(1):60-65.
32. Brown EJ, et al. (1994) A mammalian protein targeted by G1-arresting rapamycinreceptor complex. Nature 369(6483):756-758.
33. Cheng Q, Chen L, Li Z, Lane WS, Chen J (2009) ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J 28(24):3857-3867.
34. Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14(4):233-247.
35. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275(12): 8945-8951.
36. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18(1):22-27.
37. Shiloh Y, Ziv Y (2013) The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197-210.
38. Zeng YX, Somasundaram K, el-Deiry WS (1997) AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 15(1):78-82.
39. Dimri GP, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363-9367.